The Life Improvement Trial (LIFT)
The Life Improvement Trial (LIFT) aims to investigate two drugs, separately and in combination, Pyridostigmine (commonly known as Mestinon) and Low-Dose Naltrexone (LDN), for efficacy and to research the difference between responders and non-responders.
Investigation into Post-Exertional Malaise Between Historical and Recent ME/CFS
This study explores the biological changes that occur in the muscles during post-exertional malaise (PEM), both in historical cases of ME/CFS and cases of Long COVID that meet the criteria for ME/CFS.
Sleep Disturbance in ME/CFS
We intend to examine multiple sleep studies that have been conducted in the past two years and performed at the MGH Neurology Sleep Medicine Laboratory in well characterized patients with ME/CFS.
Severely iIl Patient
The goal of the Severely ill Patient Study was to conduct a comprehensive “Big Data” analysis on severely ill ME/CFS patients in order to begin an exploration to find the molecular basis of ME/CFS.
Personalized Automated Symptom Summary (PASS)
Researchers are developing a tool to help clinicians more efficiently define the character and priorities of a patient’s current symptoms of ME/CFS, Post-Treatment Lyme Disease, or Fibromyalgia.